Published 26 days ago • loading... • Updated 23 days ago

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC

Summary by onclive.com

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

pharmaceutical-technology.com

EC approves BMS’ Opdivo and Yervoy combo for HCC treatment

The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced HCC.

23 days ago

Read Full Article

pipelinereview

Bristol Myers Squibb Receives European Commission Approval for Opdivo®(nivolumab) plus Yervoy®(ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma - Pipelinereview

Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib PRINCETON, NJ, USA I March 07, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo®(nivolumab) plus Yervoy®(ipilimumab) for the first-line …

25 days ago

Read Full Article